Association between some cytokines and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation for beta-thalassemia major

doi:10.3969/j.issn.2095-4344.2014.45.011

Abstract

Abstract:

BACKGROUND: Cytokines play an important role in the occurrence and development of graft-versus-host disease, but there is a current lack of reports on the association between cytokines and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation for treatment of β-thalassemia major.
OBJECTIVE: To investigate the association between cytokines and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation for β-thalassemia major.
METHODS: We observed the dynamic variation of interleukin 6, interleukin 8, interleukin 12, tumor necrosis factor-α and macrophage migration inhibitory factor in 11 children with β-thalassemia major before onset of graft-versus-host disease, when graft-versus-host disease occurred, at days 4 and 7 after onset of graft-versus-host disease, and when graft-versus-host disease disappeared.
RESULTS AND CONCLUSION: There was a significant difference in serum levels of interleukin-6, interleukin-12, tumor necrosis factor-α, macrophage migration inhibitory factor in different time points, and the highest levels of different cytokines appeared when graft-versus-host disease occurred, followed by those at 7 days after
graft-versus-host disease. There was a significant difference in serum levels of interleukin-8 in different time points, and the highest level appeared at 4 days after graft-versus-host disease. The dynamic expression of interleukin-6, interleukin-8, interleukin-12, tumor necrosis factor-α, macrophage migration inhibitory factor can estimate the immune function of β-thalassemia major patients who develops graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, and can be used as the immunobiology indicators for the early diagnosis of graft-versus-host disease.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

全文链接：

Key words: hematopoietic stem cell transplantation, beta-thalassemia, graft vs host , cytokines

CLC Number:

R394.2

Chen Li-bai, Wen Jian-yun, Ruan Yong-sheng, Pei Fu-yu, Liu Hua-ying, He Yue-lin, Li Chun-fu, . Association between some cytokines and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation for beta-thalassemia major[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(45): 7273-7278.

Figures/Tables 2

References

[1]Martin A, Thompson AA.Thalassemias.Pediatr Clin North Am. 2013;60(6):1383-1391.
[2]Karimi M, Cohan N, De Sanctis V,et al. Guidelines for diagnosis and management of Beta-thalassemia intermedia. Pediatr Hematol Oncol. 2014;31(7):583-596.
[3]Li C, Wu X, Feng X,et al.A novel conditioning regimen improves outcomes in β-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation. Blood. 2012;120(19):3875-3881.
[4]Zhang Y, Sandy AR, Wang J,et al.Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease.Blood. 2011;117(1):299-308.
[5]Liu D, Yan C, Xu L,et al.Diarrhea during the conditioning regimen is correlated with the occurrence of severe acute graft-versus-host disease through systemic release of inflammatory cytokines.Biol Blood Marrow Transplant. 2010;16(11):1567-1575.
[6]Fall-Dickson JM, Mitchell SA, Marden S,et al.Oral symptom intensity, health-related quality of life, and correlative salivary cytokines in adult survivors of hematopoietic stem cell transplantation with oral chronic graft-versus-host disease.Biol Blood Marrow Transplant. 2010;16(7):948-956.
[7]Resende RG, Correia-Silva Jde F, Arão TC,et al.Investigation of functional IL-10 gene polymorphism and IL-10 levels in acute graft-versus-host disease.J Clin Immunol. 2010;30(3): 465-473.
[8]Miyamoto T, Akashi K, Hayashi S,et al.Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease.Bone Marrow Transplant. 1996; 17(2):185-190.
[9]Mathias C, Mick R, Grupp S,et al.Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantation.J Hematother Stem Cell Res. 2000;9(3):393-400.
[10]Choi SW, Kitko CL, Braun T,et al.Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival.Blood. 2008; 112(4):1539-1542.
[11]Berger M, Signorino E, Muraro M,et al.Monitoring of TNFR1, IL-2Rα, HGF, CCL8, IL-8 and IL-12p70 following HSCT and their role as GVHD biomarkers in paediatric patients.Bone Marrow Transplant. 2013;48(9):1230-1236.
[12]Schots R, Kaufman L, Van Riet I,et al.Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation.Leukemia. 2003; 17(6):1150-1156.
[13]Visentainer JE, Lieber SR, Persoli LB,et al. Serum cytokine levels and acute graft-versus-host disease after HLA-identical hematopoietic stem cell transplantation.Exp Hematol. 2003; 31(11):1044-1050.
[14]Weber M, Stein P, Prüfer S,et al. Donor and host B cell-derived IL-10 contributes to suppression of graft-versus- host disease.Eur J Immunol. 2014;44(6): 1857-1865.
[15]张之南,沈悌.血液病诊断及疗效标准[M].北京:科学出版社, 2007:268-271.
[16]Ferrara JL, Levine JE, Reddy P,et al. Graft-versus-host disease.Lancet. 2009;373(9674):1550-1561.
[17]Chu YW, Gress RE.Murine models of chronic graft-versus-host disease: insights and unresolved issues.Biol Blood Marrow Transplant. 2008;14(4):365-378.
[18]Lim JY, Cho BS, Min CK,et al.Fluctuations in pathogenic CD4+ T-cell subsets in a murine sclerodermatous model of chronic graft-versus-host disease.Immunol Invest. 2014; 43(1):41-53.
[19]Yi T, Chen Y, Wang L,et al.Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease.Blood. 2009;114(14):3101-3112.
[20]Sung AD, Chao NJ.Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment.Stem Cells Transl Med. 2013;2(1):25-32.
[21]Harris AC, Ferrara JL, Levine JE.Advances in predicting acute GVHD.Br J Haematol. 2013;160(3):288-302.
[22]Mosaad YM.Immunology of hematopoietic stem cell transplant. Immunol Invest. 2014;43(8):858-887.
[23]Zhang Y, Joe G, Hexner E,et al.Host-reactive CD8+ memory stem cells in graft-versus-host disease.Nat Med. 2005;11(12): 1299-1305.
[24]Hill GR, Ferrara JL.The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation.Blood. 2000;95(9):2754-2759.
[25]Manjili MH, Toor AA.Etiology of GVHD: Alloreactivity or Impaired Cellular Adaptation.Immunol Invest. 2014;43(8): 851-857.
[26]Fuchs J, Harris Z. The pathologic role of iron in infection and immunity. Contemp Critic Care. 2005;3(1):1-9.
[27]Malone FR, Leisenring WM, Storer BE,et al.Prolonged anorexia and elevated plasma cytokine levels following myeloablative allogeneic hematopoietic cell transplant.Bone Marrow Transplant. 2007;40(8):765-772.
[28]居小萍,王健民,韩凤来,等.IL-12在急性移植物抗宿主病发病机制中的作用研究[J].解放军医学杂志,2001,26(11):813-815.
[29]华佳叶,周旭红,庞缨,等.供受体血清白介素-2、肿瘤坏死因子-α水平与急性移植物抗宿主病的关系[J].南方医科大学学报, 2010, 30(4):831-833.
[30]Toubai T, Shono Y, Nishihira J,et al.Serum macrophage migration inhibitory factor (MIF) levels after allogeneic hematopoietic stem cell transplantation.Int J Lab Hematol. 2009;31(2):161-168.
[31]Lo JW, Leung AY, Huang XR,et al.Macrophage migratory inhibitory factor (MIF) expression in acute graft-versus-host disease (GVHD) in allogeneic hemopoietic stem cell transplant recipients.Bone Marrow Transplant. 2002;30(6): 375-380.